New Alzheimer’s drug rejected for NHS use – because it’s not worth the money
A new Alzheimer’s drug has been rejected for widespread use in the NHS in England after the health spending watchdog ruled it “does not currently demonstrate value for the NHS ”. The new drug, called donanemab, has been rejected for use in England’s health services by the National Institute for Health and Care Excellence ( NICE ).